Navigation Links
New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
Date:10/15/2007

PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA(TM) (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at The American College of Gastroenterology (ACG) meeting in Philadelphia.

The primary endpoint of study 303 was safety and tolerability and findings -- that LIALDA is generally well tolerated in mild to moderate UC patients -- were presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007.

"Earlier studies showed that LIALDA is well-tolerated and effective at inducing remission in patients with active, mild to moderate UC. Post-hoc analysis of secondary endpoints provided evidence that LIALDA maintained remission in a variety of UC patients," said Gary R. Lichtenstein, M.D., director of the Center for Inflammatory Bowel Diseases at the Hospital of the University of Pennsylvania.

A summary of key scientific presentations of post-hoc analyses of secondary endpoints of study 303 follows.

Once or Twice Daily LIALDA for Mild vs. Moderate Ulcerative Colitis

Poster Presentation: Tuesday, October 16, 2007, Exhibit Hall B, #950

A post-hoc analysis of secondary endpoints from the long-term 303 study was performed to review the efficacy of LIALDA for maintaining remission in patients with mild versus moderate ulcerative colitis. In the 303 study, patients were randomized to receive LIALDA 2.4g/day (given once daily [QD]) or 2.4g/day (1.2g given twice daily [BID]). Study 303 defined patient remission using stringent clinical and endoscopic measures: modified UC Disease Activity Index (UC-DAI) score of less than or equal to 1 with score
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
10. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
11. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015   InspireMD, Inc. (NYSE MKT: ... protection systems ("EPS"), today announced that its CGuard TM ... principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... c A roti D revascularization I n symptomatic ...
(Date:5/22/2015)... R.I. , May 22, 2015 ... once-daily central nervous system stimulant indicated for the ... to patients beginning Summer 2015. ... XR received approval from the U.S. Food and ... is an extended-release formulation of methylphenidate capsule with ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... Data Presented on Valopicitabine Combined,with an Investigational ... /PRNewswire-FirstCall/ --,Idenix Pharmaceuticals, Inc. today announced results ... combination of valopicitabine (NM283) and,pegylated interferon alfa-2a ... infected with the genotype-1,strain of the hepatitis ...
... 11, 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics today announced ... trials of ferumoxytol as an,intravenous (IV) iron ... approximately 6:00 pm EDT as posters at ... Orlando,Florida. These posters are available in the ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8
(Date:5/24/2015)... May 24, 2015 Women’s Excellence ... take pressure measurements in patients’ bladder and urethra. This ... orders it if they have reported symptoms of stress ... , Women’s Excellence in Bladder Control is a comprehensive ... leakage or problems with overall control of their bladder. ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) has scheduled its next monthly ... the multidistrict litigation. According to court documents filed ... Illinois, the Conference will be convened on June ... Replacement Therapy Product Liability Litigation - MDL No. ...
(Date:5/24/2015)... 24, 2015 Medicx Media Solutions ... strategy executive Jay Krihak as its head of ... ramp up its expertise and leadership position in ... and Health sectors. , Krihak is an experienced, ... recently, Krihak led sales planning teams for mobile ...
(Date:5/23/2015)... FL (PRWEB) May 23, 2015 On Saturday, ... build a new playground for Branches Florida City exactly five ... former play space in 2010. , A large fire tore ... playground on May 23, 2010 in the middle of the ... The fire was later declared arson even though it is ...
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... Calif., Nov. 30 Thoratec,Corporation (Nasdaq: THOR ... disease, said today that the FDA Circulatory System ... approve, with,conditions, the company,s PMA (PreMarket Approval) allowing ... Assist System) as a,bridge-to-transplantation (BTT)., The HeartMate ...
... with Deployed Service Members ... -, ... Operation Cares, which supports the needs of the,more than 4,000 of South Dakota,s ... central market area at,TriWest, will present the check to Steve Doohen, secretary of ...
... 30 California,s,stem cell agency is inviting for-profit ... time, the Foundation for Taxpayer and Consumer Rights,(FTCR) ... vowed to scrutinize the awards process to prevent ... (CIRM) has just,issued calls for applications for two ...
... The following is a,statement from Henrietta H. ... international community again recognizes World AIDS,Day and the ... living with,HIV/AIDS. Through the President,s Emergency Plan for ... (USAID) is supporting those,battling the disease, as well ...
... Va., Nov. 30 The Pharmaceutical,Care Management ... claiming,that pending legislation requiring prompt payment of ... billions of dollars. PCMA represents 10,pharmacy benefit ... drug plans. In response, Bruce Roberts, RPh, ...
... LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. ... Philippe Calais, PhD.,Pharm., Neurochem,s President, Global Business. Dr. ... December 31, 2007, to pursue other,interests., "Dr. ... relationships for Neurochem in international markets and we,are ...
Cached Medicine News:Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 2Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 3Health News:TriWest Contributes $10,000 to Operation Cares for South Dakota's Military Families 2Health News:Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say 2Health News:On World AIDS Day, Keeping the Promise to Stop AIDS Through the Power of Partnerships 2Health News:NCPA Statement on Bogus PCMA Study About Cost to Fix Medicare Part D 2Health News:Neurochem announces departure of Dr. Philippe Calais, President, Global Business 2
... The new DeVilbiss PulmoAide Compact Compressor provides effective ... size allows for therapy at home or on ... 5-year warranty, and the same reliable operation you ... ,The PulmoAide Compact Compressor is the perfect solution ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
Medicine Products: